25 XP   0   0   10

Medigen Vaccine Biologics
Buy, Hold or Sell?

Let's analyse Medigen Vaccine Biologics together

PenkeI guess you are interested in Medigen Vaccine Biologics. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Medigen Vaccine Biologics. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Medigen Vaccine Biologics

I send you an email if I find something interesting about Medigen Vaccine Biologics.

Quick analysis of Medigen Vaccine Biologics (30 sec.)










What can you expect buying and holding a share of Medigen Vaccine Biologics? (30 sec.)

How much money do you get?

How much money do you get?
NT$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
NT$11.71
Expected worth in 1 year
NT$8.11
How sure are you?
35.7%

+ What do you gain per year?

Total Gains per Share
NT$-3.60
Return On Investment
-7.1%

For what price can you sell your share?

Current Price per Share
NT$50.70
Expected price per share
NT$51.50 - NT$56.40
How sure are you?
50%

1. Valuation of Medigen Vaccine Biologics (5 min.)




Live pricePrice per Share (EOD)

NT$50.70

Intrinsic Value Per Share

NT$17.51 - NT$21.68

Total Value Per Share

NT$29.21 - NT$33.39

2. Growth of Medigen Vaccine Biologics (5 min.)




Is Medigen Vaccine Biologics growing?

Current yearPrevious yearGrowGrow %
How rich?$119.2m$164.4m-$28.2m-20.8%

How much money is Medigen Vaccine Biologics making?

Current yearPrevious yearGrowGrow %
Making money-$8.9m-$11.4m$2.4m27.1%
Net Profit Margin-90.9%-5,070.0%--

How much money comes from the company's main activities?

3. Financial Health of Medigen Vaccine Biologics (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#348 / 1019

Most Revenue
#400 / 1019

Most Profit
#533 / 1019

Most Efficient
#567 / 1019

What can you expect buying and holding a share of Medigen Vaccine Biologics? (5 min.)

Welcome investor! Medigen Vaccine Biologics's management wants to use your money to grow the business. In return you get a share of Medigen Vaccine Biologics.

What can you expect buying and holding a share of Medigen Vaccine Biologics?

First you should know what it really means to hold a share of Medigen Vaccine Biologics. And how you can make/lose money.

Speculation

The Price per Share of Medigen Vaccine Biologics is NT$50.70. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Medigen Vaccine Biologics.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Medigen Vaccine Biologics, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is NT$11.71. Based on the TTM, the Book Value Change Per Share is NT$-0.90 per quarter. Based on the YOY, the Book Value Change Per Share is NT$0.27 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is NT$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Medigen Vaccine Biologics.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 NT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per ShareNT$% of Price per Share
Usd Eps-0.05-0.1%-0.03-0.1%-0.03-0.1%-0.010.0%-0.010.0%
Usd Book Value Change Per Share-0.05-0.1%-0.03-0.1%0.010.0%0.030.1%0.030.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.05-0.1%-0.03-0.1%0.010.0%0.030.1%0.030.1%
Usd Price Per Share2.17-2.03-4.80-4.84-4.84-
Price to Earnings Ratio-9.89--40.85--59.86--49.99--49.99-
Price-to-Total Gains Ratio-40.57--120.44--318.78--202.30--202.30-
Price to Book Ratio5.99-4.97-9.90-14.18-14.18-
Price-to-Total Gains Ratio-40.57--120.44--318.78--202.30--202.30-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share1.5717
Number of shares636
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.030.03
Usd Total Gains Per Share-0.030.03
Gains per Quarter (636 shares)-17.7416.48
Gains per Year (636 shares)-70.9465.94
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-71-8106656
20-142-1520132122
30-213-2230198188
40-284-2940264254
50-355-3650330320
60-426-4360396386
70-497-5070462452
80-568-5780528518
90-638-6490593584
100-709-7200659650

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%2.010.00.016.7%2.012.00.014.3%2.012.00.014.3%2.012.00.014.3%
Book Value Change Per Share0.04.00.00.0%3.09.00.025.0%5.09.00.035.7%5.09.00.035.7%5.09.00.035.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.014.00.0%0.00.014.00.0%0.00.014.00.0%
Total Gains per Share0.04.00.00.0%3.09.00.025.0%5.09.00.035.7%5.09.00.035.7%5.09.00.035.7%

Fundamentals of Medigen Vaccine Biologics

About Medigen Vaccine Biologics

Medigen Vaccine Biologics Corporation, a biotechnology drug company, focuses on the development and production of vaccines and biologics in Taiwan and internationally. The company is developing enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection; influenza vaccine, which has completed Phase III clinical trial to treat influenza; dengue vaccine, which has completed Phase II clinical trial for the treatment of dengue fever; respiratory cell fusion virus (RSV) antibody, which is in Phase I clinical trial for the prevention of RSV infection; and COVID-19 vaccine, which is in Phase III clinical trial to prevent COVID-19- severe special infectious pneumonia. Medigen Vaccine Biologics Corporation was founded in 2012 and is based in Taipei, Taiwan. Medigen Vaccine Biologics Corporation is a subsidiary of Medigen Biotechnology Corp.

Fundamental data was last updated by Penke on 2024-03-30 03:03:03.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is overpriced.

1.1. Profitability of Medigen Vaccine Biologics.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Medigen Vaccine Biologics earns for each NT$1 of revenue.

  • Above 10% is considered healthy but always compare Medigen Vaccine Biologics to the Biotechnology industry mean.
  • A Net Profit Margin of -339.8% means that NT$-3.40 for each NT$1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Medigen Vaccine Biologics:

  • The MRQ is -339.8%. The company is making a huge loss. -2
  • The TTM is -90.9%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-339.8%TTM-90.9%-248.9%
TTM-90.9%YOY-5,070.0%+4,979.1%
TTM-90.9%5Y-3,828.2%+3,737.3%
5Y-3,828.2%10Y-3,828.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-339.8%-196.9%-142.9%
TTM-90.9%-211.2%+120.3%
YOY-5,070.0%-279.3%-4,790.7%
5Y-3,828.2%-436.8%-3,391.4%
10Y-3,828.2%-599.3%-3,228.9%
1.1.2. Return on Assets

Shows how efficient Medigen Vaccine Biologics is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Medigen Vaccine Biologics to the Biotechnology industry mean.
  • -9.6% Return on Assets means that Medigen Vaccine Biologics generated NT$-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Medigen Vaccine Biologics:

  • The MRQ is -9.6%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -4.5%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-9.6%TTM-4.5%-5.0%
TTM-4.5%YOY-5.0%+0.5%
TTM-4.5%5Y-1.8%-2.7%
5Y-1.8%10Y-1.8%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9.6%-13.6%+4.0%
TTM-4.5%-12.9%+8.4%
YOY-5.0%-11.9%+6.9%
5Y-1.8%-14.2%+12.4%
10Y-1.8%-16.2%+14.4%
1.1.3. Return on Equity

Shows how efficient Medigen Vaccine Biologics is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Medigen Vaccine Biologics to the Biotechnology industry mean.
  • -15.1% Return on Equity means Medigen Vaccine Biologics generated NT$-0.15 for each NT$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Medigen Vaccine Biologics:

  • The MRQ is -15.1%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -6.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.1%TTM-6.9%-8.2%
TTM-6.9%YOY-7.0%+0.1%
TTM-6.9%5Y-3.2%-3.8%
5Y-3.2%10Y-3.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.1%-17.0%+1.9%
TTM-6.9%-16.1%+9.2%
YOY-7.0%-15.4%+8.4%
5Y-3.2%-20.0%+16.8%
10Y-3.2%-21.1%+17.9%

1.2. Operating Efficiency of Medigen Vaccine Biologics.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Medigen Vaccine Biologics is operating .

  • Measures how much profit Medigen Vaccine Biologics makes for each NT$1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Medigen Vaccine Biologics to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated NT$0.00  for each NT$1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Medigen Vaccine Biologics:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-5,813.5%+5,813.5%
TTM-5Y-6,543.6%+6,543.6%
5Y-6,543.6%10Y-6,543.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--282.4%+282.4%
TTM--225.8%+225.8%
YOY-5,813.5%-288.4%-5,525.1%
5Y-6,543.6%-475.2%-6,068.4%
10Y-6,543.6%-624.7%-5,918.9%
1.2.2. Operating Ratio

Measures how efficient Medigen Vaccine Biologics is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 4.49 means that the operating costs are NT$4.49 for each NT$1 in net sales.

Let's take a look of the Operating Ratio trends of Medigen Vaccine Biologics:

  • The MRQ is 4.492. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.595. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ4.492TTM1.595+2.897
TTM1.595YOY64.249-62.653
TTM1.5955Y68.279-66.684
5Y68.27910Y68.2790.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.4922.994+1.498
TTM1.5953.247-1.652
YOY64.2493.766+60.483
5Y68.2795.675+62.604
10Y68.2797.857+60.422

1.3. Liquidity of Medigen Vaccine Biologics.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Medigen Vaccine Biologics is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.21 means the company has NT$2.21 in assets for each NT$1 in short-term debts.

Let's take a look of the Current Ratio trends of Medigen Vaccine Biologics:

  • The MRQ is 2.210. The company is able to pay all its short-term debts. +1
  • The TTM is 8.428. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ2.210TTM8.428-6.218
TTM8.428YOY15.267-6.839
TTM8.4285Y9.471-1.043
5Y9.47110Y9.4710.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.2103.930-1.720
TTM8.4284.251+4.177
YOY15.2675.436+9.831
5Y9.4716.045+3.426
10Y9.4716.383+3.088
1.3.2. Quick Ratio

Measures if Medigen Vaccine Biologics is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Medigen Vaccine Biologics to the Biotechnology industry mean.
  • A Quick Ratio of 1.26 means the company can pay off NT$1.26 for each NT$1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Medigen Vaccine Biologics:

  • The MRQ is 1.262. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 5.226. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ1.262TTM5.226-3.964
TTM5.226YOY6.623-1.397
TTM5.2265Y4.227+0.999
5Y4.22710Y4.2270.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.2623.629-2.367
TTM5.2264.065+1.161
YOY6.6235.390+1.233
5Y4.2275.993-1.766
10Y4.2276.277-2.050

1.4. Solvency of Medigen Vaccine Biologics.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Medigen Vaccine Biologics assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Medigen Vaccine Biologics to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.37 means that Medigen Vaccine Biologics assets are financed with 36.9% credit (debt) and the remaining percentage (100% - 36.9%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Medigen Vaccine Biologics:

  • The MRQ is 0.369. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.334. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.369TTM0.334+0.035
TTM0.334YOY0.252+0.082
TTM0.3345Y0.254+0.080
5Y0.25410Y0.2540.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3690.332+0.037
TTM0.3340.333+0.001
YOY0.2520.268-0.016
5Y0.2540.366-0.112
10Y0.2540.390-0.136
1.4.2. Debt to Equity Ratio

Measures if Medigen Vaccine Biologics is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Medigen Vaccine Biologics to the Biotechnology industry mean.
  • A Debt to Equity ratio of 58.4% means that company has NT$0.58 debt for each NT$1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Medigen Vaccine Biologics:

  • The MRQ is 0.584. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.503. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.584TTM0.503+0.081
TTM0.503YOY0.349+0.154
TTM0.5035Y0.362+0.142
5Y0.36210Y0.3620.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5840.380+0.204
TTM0.5030.389+0.114
YOY0.3490.334+0.015
5Y0.3620.432-0.070
10Y0.3620.465-0.103

2. Market Valuation of Medigen Vaccine Biologics

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every NT$1 in earnings Medigen Vaccine Biologics generates.

  • Above 15 is considered overpriced but always compare Medigen Vaccine Biologics to the Biotechnology industry mean.
  • A PE ratio of -9.89 means the investor is paying NT$-9.89 for every NT$1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Medigen Vaccine Biologics:

  • The EOD is -7.155. Based on the earnings, the company is expensive. -2
  • The MRQ is -9.893. Based on the earnings, the company is expensive. -2
  • The TTM is -40.850. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.155MRQ-9.893+2.738
MRQ-9.893TTM-40.850+30.957
TTM-40.850YOY-59.858+19.008
TTM-40.8505Y-49.995+9.145
5Y-49.99510Y-49.9950.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.155-2.426-4.729
MRQ-9.893-2.552-7.341
TTM-40.850-2.656-38.194
YOY-59.858-4.143-55.715
5Y-49.995-6.252-43.743
10Y-49.995-6.108-43.887
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Medigen Vaccine Biologics:

  • The EOD is 238.935. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is 330.361. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is 50.086. Based on how much money comes from the company's main activities, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD238.935MRQ330.361-91.427
MRQ330.361TTM50.086+280.275
TTM50.086YOY-82.786+132.871
TTM50.0865Y-42.483+92.569
5Y-42.48310Y-42.4830.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD238.935-3.199+242.134
MRQ330.361-3.259+333.620
TTM50.086-3.552+53.638
YOY-82.786-5.617-77.169
5Y-42.483-8.326-34.157
10Y-42.483-8.689-33.794
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Medigen Vaccine Biologics is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.99 means the investor is paying NT$5.99 for each NT$1 in book value.

Let's take a look of the Price to Book Ratio trends of Medigen Vaccine Biologics:

  • The EOD is 4.331. Based on the equity, the company is fair priced.
  • The MRQ is 5.989. Based on the equity, the company is overpriced. -1
  • The TTM is 4.965. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD4.331MRQ5.989-1.657
MRQ5.989TTM4.965+1.023
TTM4.965YOY9.900-4.935
TTM4.9655Y14.184-9.219
5Y14.18410Y14.1840.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD4.3311.947+2.384
MRQ5.9892.116+3.873
TTM4.9652.095+2.870
YOY9.9002.836+7.064
5Y14.1843.443+10.741
10Y14.1843.791+10.393
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Medigen Vaccine Biologics compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.728-0.900-48%0.269-744%0.836-307%0.836-307%
Book Value Per Share--11.70613.369-12%16.145-27%12.497-6%12.497-6%
Current Ratio--2.2108.428-74%15.267-86%9.471-77%9.471-77%
Debt To Asset Ratio--0.3690.334+10%0.252+46%0.254+45%0.254+45%
Debt To Equity Ratio--0.5840.503+16%0.349+67%0.362+61%0.362+61%
Dividend Per Share----0%-0%-0%-0%
Eps---1.772-0.882-50%-1.122-37%-0.347-80%-0.347-80%
Free Cash Flow Per Share--0.053-0.395+845%-0.944+1880%-0.364+786%-0.364+786%
Free Cash Flow To Equity Per Share--0.053-0.393+841%1.584-97%0.706-92%0.706-92%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--21.679--------
Intrinsic Value_10Y_min--17.505--------
Intrinsic Value_1Y_max---0.828--------
Intrinsic Value_1Y_min---0.815--------
Intrinsic Value_3Y_max---0.201--------
Intrinsic Value_3Y_min---0.238--------
Intrinsic Value_5Y_max--3.182--------
Intrinsic Value_5Y_min--2.757--------
Market Cap16660425600.000-38%23035420800.00021556684800.000+7%50932013680.800-55%51337892678.400-55%51337892678.400-55%
Net Profit Margin---3.398-0.909-73%-50.700+1392%-38.282+1027%-38.282+1027%
Operating Margin----0%-58.1350%-65.4360%-65.4360%
Operating Ratio--4.4921.595+182%64.249-93%68.279-93%68.279-93%
Pb Ratio4.331-38%5.9894.965+21%9.900-40%14.184-58%14.184-58%
Pe Ratio-7.155+28%-9.893-40.850+313%-59.858+505%-49.995+405%-49.995+405%
Price Per Share50.700-38%70.10065.600+7%154.993-55%156.228-55%156.228-55%
Price To Free Cash Flow Ratio238.935-38%330.36150.086+560%-82.786+125%-42.483+113%-42.483+113%
Price To Total Gains Ratio-29.339+28%-40.565-120.445+197%-318.782+686%-202.301+399%-202.301+399%
Quick Ratio--1.2625.226-76%6.623-81%4.227-70%4.227-70%
Return On Assets---0.096-0.045-53%-0.050-48%-0.018-81%-0.018-81%
Return On Equity---0.151-0.069-54%-0.070-54%-0.032-79%-0.032-79%
Total Gains Per Share---1.728-0.900-48%0.269-744%0.836-307%0.836-307%
Usd Book Value--119243949.000136191517.250-12%164470453.500-27%127304192.571-6%127304192.571-6%
Usd Book Value Change Per Share---0.054-0.028-48%0.008-744%0.026-307%0.026-307%
Usd Book Value Per Share--0.3630.414-12%0.501-27%0.387-6%0.387-6%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.055-0.027-50%-0.035-37%-0.011-80%-0.011-80%
Usd Free Cash Flow--540392.000-4024466.500+845%-9620121.500+1880%-3709778.857+786%-3709778.857+786%
Usd Free Cash Flow Per Share--0.002-0.012+845%-0.029+1880%-0.011+786%-0.011+786%
Usd Free Cash Flow To Equity Per Share--0.002-0.012+841%0.049-97%0.022-92%0.022-92%
Usd Market Cap516473193.600-38%714098044.800668257228.800+7%1578892424.105-55%1591474673.030-55%1591474673.030-55%
Usd Price Per Share1.572-38%2.1732.034+7%4.805-55%4.843-55%4.843-55%
Usd Profit---18046185.000-8988721.250-50%-11427940.750-37%-3529927.929-80%-3529927.929-80%
Usd Revenue--5311478.0003019586.000+76%2829075.500+88%8957972.571-41%8957972.571-41%
Usd Total Gains Per Share---0.054-0.028-48%0.008-744%0.026-307%0.026-307%
 EOD+4 -4MRQTTM+10 -22YOY+9 -235Y+8 -2410Y+8 -24

3.2. Fundamental Score

Let's check the fundamental score of Medigen Vaccine Biologics based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.155
Price to Book Ratio (EOD)Between0-14.331
Net Profit Margin (MRQ)Greater than0-3.398
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.262
Current Ratio (MRQ)Greater than12.210
Debt to Asset Ratio (MRQ)Less than10.369
Debt to Equity Ratio (MRQ)Less than10.584
Return on Equity (MRQ)Greater than0.15-0.151
Return on Assets (MRQ)Greater than0.05-0.096
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Medigen Vaccine Biologics based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose52.000
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in TWD. All numbers in thousands.

Summary
Total Assets6,092,646
Total Liabilities2,246,067
Total Stockholder Equity3,846,579
 As reported
Total Liabilities 2,246,067
Total Stockholder Equity+ 3,846,579
Total Assets = 6,092,646

Assets

Total Assets6,092,646
Total Current Assets4,401,325
Long-term Assets1,691,321
Total Current Assets
Cash And Cash Equivalents 1,393,120
Short-term Investments 2,364,100
Net Receivables 149,107
Inventory 383,635
Other Current Assets 48,136
Total Current Assets  (as reported)4,401,325
Total Current Assets  (calculated)4,338,098
+/- 63,227
Long-term Assets
Property Plant Equipment 1,384,531
Long-term Assets Other 6,826
Long-term Assets  (as reported)1,691,321
Long-term Assets  (calculated)1,391,357
+/- 299,964

Liabilities & Shareholders' Equity

Total Current Liabilities1,991,711
Long-term Liabilities254,356
Total Stockholder Equity3,846,579
Total Current Liabilities
Short Long Term Debt 1,708,101
Accounts payable 25,885
Other Current Liabilities 610
Total Current Liabilities  (as reported)1,991,711
Total Current Liabilities  (calculated)1,734,596
+/- 257,115
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt266,352
Long-term Liabilities  (as reported)254,356
Long-term Liabilities  (calculated)266,352
+/- 11,996
Total Stockholder Equity
Total Stockholder Equity (as reported)3,846,579
Total Stockholder Equity (calculated)0
+/- 3,846,579
Other
Capital Stock3,286,081
Common Stock Shares Outstanding 328,608
Net Debt 314,981
Net Invested Capital 5,554,680
Net Working Capital 2,409,614
Property Plant and Equipment Gross 1,384,531



Balance Sheet

Currency in TWD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-30
> Total Assets 
2,222,292
3,490,814
3,469,478
4,117,292
4,456,056
5,299,011
5,227,631
8,255,460
7,971,701
7,347,689
6,980,820
6,652,712
6,621,471
6,092,646
6,092,6466,621,4716,652,7126,980,8207,347,6897,971,7018,255,4605,227,6315,299,0114,456,0564,117,2923,469,4783,490,8142,222,292
   > Total Current Assets 
482,989
2,009,680
1,950,639
2,587,128
2,895,851
3,721,246
3,465,614
6,386,561
6,117,805
5,462,422
5,141,917
4,907,087
4,925,298
4,401,325
4,401,3254,925,2984,907,0875,141,9175,462,4226,117,8056,386,5613,465,6143,721,2462,895,8512,587,1281,950,6392,009,680482,989
       Cash And Cash Equivalents 
296,110
1,679,422
380,016
855,488
814,372
1,379,692
1,267,943
4,520,199
1,148,425
1,204,255
1,021,601
683,967
538,654
1,393,120
1,393,120538,654683,9671,021,6011,204,2551,148,4254,520,1991,267,9431,379,692814,372855,488380,0161,679,422296,110
       Short-term Investments 
53,139
53,170
1,153,133
561,167
365,134
853,097
853,063
52,849
3,047,338
3,032,933
3,159,000
3,182,920
3,205,520
2,364,100
2,364,1003,205,5203,182,9203,159,0003,032,9333,047,33852,849853,063853,097365,134561,1671,153,13353,17053,139
       Net Receivables 
1,905
130,715
127,017
137,254
536,382
640,259
474,367
454,072
468,967
195,571
6,303
26,593
117,210
149,107
149,107117,21026,5936,303195,571468,967454,072474,367640,259536,382137,254127,017130,7151,905
       Inventory 
40,436
77,432
92,366
750,529
805,626
563,495
593,008
750,338
1,267,776
903,401
897,900
952,752
840,773
383,635
383,635840,773952,752897,900903,4011,267,776750,338593,008563,495805,626750,52992,36677,43240,436
       Other Current Assets 
52,135
51,639
67,747
202,694
220,827
205,071
174,664
186,157
164,493
113,893
44,071
62,648
55,878
48,136
48,13655,87862,64844,071113,893164,493186,157174,664205,071220,827202,69467,74751,63952,135
   > Long-term Assets 
1,739,303
1,481,134
1,518,839
1,530,164
1,560,205
1,577,765
1,762,017
1,868,899
1,853,896
1,885,267
1,838,903
1,745,625
1,696,173
1,691,321
1,691,3211,696,1731,745,6251,838,9031,885,2671,853,8961,868,8991,762,0171,577,7651,560,2051,530,1641,518,8391,481,1341,739,303
       Property Plant Equipment 
1,629,172
1,343,416
1,353,072
1,346,024
1,339,290
1,413,529
1,501,197
1,496,432
1,473,687
1,469,525
1,455,539
1,429,321
1,401,098
1,384,531
1,384,5311,401,0981,429,3211,455,5391,469,5251,473,6871,496,4321,501,1971,413,5291,339,2901,346,0241,353,0721,343,4161,629,172
       Other Assets 
54,083
77,707
53,807
74,023
112,158
57,258
30,274
71,826
96,581
106,825
97,544
15,443
0
0
0015,44397,544106,82596,58171,82630,27457,258112,15874,02353,80777,70754,083
> Total Liabilities 
820,005
349,404
445,218
1,246,800
873,439
622,954
631,448
2,392,224
2,238,131
2,318,684
2,166,055
2,155,394
2,207,034
2,246,067
2,246,0672,207,0342,155,3942,166,0552,318,6842,238,1312,392,224631,448622,954873,4391,246,800445,218349,404820,005
   > Total Current Liabilities 
183,752
160,975
257,286
1,060,364
689,075
439,087
356,590
452,279
279,975
355,232
194,868
1,895,041
1,949,679
1,991,711
1,991,7111,949,6791,895,041194,868355,232279,975452,279356,590439,087689,0751,060,364257,286160,975183,752
       Short Long Term Debt 
30,020
597
828
14,167
1,774
1,730
82
4,758
1,955
581
200
1,692,844
1,700,425
1,708,101
1,708,1011,700,4251,692,8442005811,9554,758821,7301,77414,16782859730,020
       Accounts payable 
15,925
21,776
28,117
61,124
108,945
88,534
79,659
131,158
80,095
109,101
19,906
19,970
6,712
25,885
25,8856,71219,97019,906109,10180,095131,15879,65988,534108,94561,12428,11721,77615,925
       Other Current Liabilities 
50,168
137,271
227,226
779,522
578,158
348,566
265,247
43,372
188,155
234,353
163,103
170,346
602
610
610602170,346163,103234,353188,15543,372265,247348,566578,158779,522227,226137,27150,168
   > Long-term Liabilities 
636,253
188,429
187,932
186,436
184,364
183,867
274,858
1,939,945
1,958,156
1,963,452
1,971,187
260,353
257,355
254,356
254,356257,355260,3531,971,1871,963,4521,958,1561,939,945274,858183,867184,364186,436187,932188,429636,253
       Long term Debt 
297,935
0
0
0
0
0
0
1,662,804
1,670,310
1,677,850
1,685,259
0
0
0
0001,685,2591,677,8501,670,3101,662,804000000297,935
       Capital Lease Obligations Min Short Term Debt
344,763
187,782
187,300
186,818
186,336
185,854
286,542
283,912
281,021
278,130
275,212
272,294
269,377
266,352
266,352269,377272,294275,212278,130281,021283,912286,542185,854186,336186,818187,300187,782344,763
       Other Liabilities 
2,575
2,575
2,575
1,575
0
0
0
4,900
18,550
19,250
22,575
0
0
0
00022,57519,25018,5504,9000001,5752,5752,5752,575
       Long-term Liabilities Other 
2,575
2,575
2,575
1,575
0
0
0
0
0
0
0
0
0
0
00000000001,5752,5752,5752,575
> Total Stockholder Equity
1,402,287
3,141,410
3,024,260
2,870,492
3,582,617
4,676,057
4,596,183
5,863,236
5,733,570
5,029,005
4,814,765
4,497,318
4,414,437
3,846,579
3,846,5794,414,4374,497,3184,814,7655,029,0055,733,5705,863,2364,596,1834,676,0573,582,6172,870,4923,024,2603,141,4101,402,287
   Common Stock
1,867,168
2,110,988
2,114,608
2,123,220
2,124,920
2,128,865
2,131,248
2,134,786
3,271,981
3,278,399
3,280,312
3,283,568
0
0
003,283,5683,280,3123,278,3993,271,9812,134,7862,131,2482,128,8652,124,9202,123,2202,114,6082,110,9881,867,168
   Retained Earnings Total Equity00000000000000
   Accumulated Other Comprehensive Income 00000000000000
   Capital Surplus 00000000000000
   Treasury Stock00000000000000
   Other Stockholders Equity 
3,552
3,266
8,265
1,263
3,506
1,924
31,709
1,230,625
91,241
84,031
64,497
1,597,934
0
0
001,597,93464,49784,03191,2411,230,62531,7091,9243,5061,2638,2653,2663,552



Balance Sheet

Currency in TWD. All numbers in thousands.




Cash Flow

Currency in TWD. All numbers in thousands.




Income Statement

Currency in TWD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue389,624
Cost of Revenue-159,402
Gross Profit230,222230,222
 
Operating Income (+$)
Gross Profit230,222
Operating Expense-1,603,453
Operating Income-1,213,829-1,373,231
 
Operating Expense (+$)
Research Development1,200,614
Selling General Administrative243,437
Selling And Marketing Expenses0
Operating Expense1,603,4531,444,051
 
Net Interest Income (+$)
Interest Income83,282
Interest Expense-37,571
Other Finance Cost-0
Net Interest Income45,711
 
Pretax Income (+$)
Operating Income-1,213,829
Net Interest Income45,711
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-1,159,835-1,213,829
EBIT - interestExpense = -37,571
-1,159,835
-1,122,264
Interest Expense37,571
Earnings Before Interest and Taxes (EBIT)0-1,122,264
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax-1,159,835
Tax Provision-0
Net Income From Continuing Ops-1,159,835-1,159,835
Net Income-1,159,835
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-45,711
 

Technical Analysis of Medigen Vaccine Biologics
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Medigen Vaccine Biologics. The general trend of Medigen Vaccine Biologics is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Medigen Vaccine Biologics's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Medigen Vaccine Biologics.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 55.40 < 55.70 < 56.40.

The bearish price targets are: 51.50.

Tweet this
Medigen Vaccine Biologics Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Medigen Vaccine Biologics. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Medigen Vaccine Biologics Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Medigen Vaccine Biologics.

Medigen Vaccine Biologics Daily Moving Average Convergence/Divergence (MACD) ChartMedigen Vaccine Biologics Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Medigen Vaccine Biologics. The current adx is .

Medigen Vaccine Biologics Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Medigen Vaccine Biologics.

Medigen Vaccine Biologics Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Medigen Vaccine Biologics.

Medigen Vaccine Biologics Daily Relative Strength Index (RSI) ChartMedigen Vaccine Biologics Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Medigen Vaccine Biologics.

Medigen Vaccine Biologics Daily Stochastic Oscillator ChartMedigen Vaccine Biologics Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Medigen Vaccine Biologics.

Medigen Vaccine Biologics Daily Commodity Channel Index (CCI) ChartMedigen Vaccine Biologics Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Medigen Vaccine Biologics.

Medigen Vaccine Biologics Daily Chande Momentum Oscillator (CMO) ChartMedigen Vaccine Biologics Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Medigen Vaccine Biologics.

Medigen Vaccine Biologics Daily Williams %R ChartMedigen Vaccine Biologics Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Medigen Vaccine Biologics.

Medigen Vaccine Biologics Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Medigen Vaccine Biologics.

Medigen Vaccine Biologics Daily Average True Range (ATR) ChartMedigen Vaccine Biologics Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Medigen Vaccine Biologics.

Medigen Vaccine Biologics Daily On-Balance Volume (OBV) ChartMedigen Vaccine Biologics Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Medigen Vaccine Biologics.

Medigen Vaccine Biologics Daily Money Flow Index (MFI) ChartMedigen Vaccine Biologics Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Medigen Vaccine Biologics.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-14CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-11-16STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-11-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-28MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-11-30WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-01CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-06RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-11STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-14WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-27MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-03MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-05STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-09CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-12ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-15SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-18CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-19SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-25BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-05CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-11ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-20STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-03-26STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-01SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-03STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Medigen Vaccine Biologics Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Medigen Vaccine Biologics based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose52.000
Total1/1 (100.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Medigen Vaccine Biologics with someone you think should read this too:
  • Are you bullish or bearish on Medigen Vaccine Biologics? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Medigen Vaccine Biologics? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Medigen Vaccine Biologics

I send you an email if I find something interesting about Medigen Vaccine Biologics.


Comments

How you think about this?

Leave a comment

Stay informed about Medigen Vaccine Biologics.

Receive notifications about Medigen Vaccine Biologics in your mailbox!